Fibroblast-like synoviocytes (FLS) are important components of the synovial membrane. They can contribute to joint damage through crosstalk with inflammatory cells and direct actions on tissue damage pathways in rheumatoid arthritis (RA). Recent evidence suggests that, compared with FLS in normal synovial tissue, FLS in RA synovial tissue exhibits significant differences in metabolism. Recent metabolomic studies have demonstrated that metabolic changes, including those in glucose, lipid, and amino acid metabolism, exist before synovitis onset. These changes may be a result of increased biosynthesis and energy requirements during the early phases of the disease. Activated T cells and some cytokines contribute to the conversion of FLS into cells with metabolic abnormalities and pro-inflammatory phenotypes. This conversion may be one of the potential mechanisms behind altered FLS metabolism. Targeting metabolism can inhibit FLS proliferation, providing relief to patients with RA. In this review, we aimed to summarize the evidence of metabolic changes in FLS in RA, analyze the mechanisms of these metabolic alterations, and assess their effect on RA phenotype. Finally, we aimed to summarize the advances and challenges faced in targeting FLS metabolism as a promising therapeutic strategy for RA in the future.
Diabetes mellitus (DM), a complex metabolic disorder with severe complications, has been established to impose a heavy burden on patients and medical systems globally. Furthermore, it has been reported that contemporary therapeutic approaches or medications may not effectively manage DM. Lycium barbarum polysaccharide (LBP), a bioactive compound isolated from Lycium barbarum L. fruits, was shown to improve glycolipid parameters and mitigate glucotoxicity-induced target organ damage, making it a promising multifunctional hypoglycemic agent. Here, based on basic and clinical studies conducted over the past 20 years, we comprehensively review the potential benefits and molecular mechanisms of LBP in preventing and combating DM and its chronic complications. Our analysis revealed that LBP can reduce intestinal glucose digestion and absorption, improve glycolipid metabolism and insulin sensitivity, protect pancreatic β -cell function, inhibit oxidative stress (OS) and inflammatory responses, and regulate gut microbiota (GM), thus alleviating DM. It also exhibited significant pharmacological value in addressing the critical pathological mechanisms underlying DM-related complications. Despite the promising preclinical evidence, further exploration of LBP’s bioavailability, toxicology, structure–activity, and dose-effect relationships would still be required before clinical translation studies. We hope that our findings will lay a proper therapeutic and molecular foundation for future LBP-related research and product development in relation to treating DM and its associated complications.
3 January 2025 in BMC Complementary Medicine and Therapies
Frailty is a common geriatric syndrome worldwide, and its early identification and intervention have important clinical significance. Resistance training has been recommended as an efficient means to combat loss of muscle strength and mass; however, it is often not a prioritized option for older adults. Tai chi is a well-known traditional Chinese exercise that has a beneficial impact on physical performance, balance ability, metabolism, and immune function. With the newly emerged concept of muscle-immune homeostasis, this study focused on determining the efficacy of tai chi prefrail older adults who develop immunosenescence. Furthermore, the proper timing of the exercise regimen for maximizing the therapeutic effect of tai chi has also been explored. This 12-week, multicenter, randomized controlled trial (RCT) was conducted with participants between 60 and 75 years of age. A total of 144 prefrail participants were included in this study and were randomized (1:1:1:1) to four groups: (1) a control group with only health education, (2) a morning tai chi group, (3) a morning resistance training group, and (4) an afternoon tai chi group. The primary endpoints included physical performance, frailty index scores, muscle strength, and mass, and the secondary endpoints were the sarcopenia quality of life score, Berg balance scale score, bioenergetic anti-stress index (BASI), and immune risk profile (IRP). The data were analyzed according to the intention-to-treat protocol. The results of this investigation aided in determining whether tai chi effectively reversed the prefrail state of older adults and ameliorated biomarkers of immunosenescence. Furthermore, proper exercise timing was also determined to maximize the efficacy of physical training. Chinese Clinical Trial Registry; registration number: ChiCTR2200065815; prospectively registered on November 16th, 2022.
16 February 2026 in Chinese Journal of Natural Medicines